---
title: "BlossomHill Therapeutics, Inc. 3Q 2026: Net loss $(23.8) M, EPS $(8.75) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299442935.md"
description: "BlossomHill Therapeutics reported a net loss of $23.8M and diluted EPS of $(8.75) for Q3 2026, widening from the prior year's $13.2M loss. The company generated no revenue as it remains clinical-stage. Key developments include enrollment in the SOLARA Phase 1/2 trial for BH-30643, ongoing dose escalation for BH-30236 in AML/MDS, and preclinical work on BH-501284. Cash reserves are expected to fund operations through Q2 2028."
datetime: "2026-09-18T11:41:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299442935.md)
  - [en](https://longbridge.com/en/news/299442935.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299442935.md)
generator: "portal-rs"
---

# BlossomHill Therapeutics, Inc. 3Q 2026: Net loss $(23.8) M, EPS $(8.75) — 10-Q Summary

BlossomHill Therapeutics, Inc. reported a net loss of $(23.8) M for the three months ended June 30, 2026, compared with a $(13.2) M loss in the year-ago quarter; diluted loss per share was $(8.75) versus $(5.51) in the prior-year quarter. The company reported no product revenue for the periods presented as it continues to operate as a clinical-stage biopharmaceutical company.

**Financial Highlights**

-   Net income: $(23.8) M net loss for the three months ended June 30, 2026, versus $(13.2) M in the year-ago quarter (≈ $(10.5) M wider YoY).
-   Diluted EPS: $(8.75) for the three months ended June 30, 2026, versus $(5.51) in the year-ago quarter.
-   Revenue: Not reported for the periods presented (company has no product sales; all periods show net loss).

**Business Highlights**

-   Clinical progress: SOLARA Phase 1/2 is enrolling for BH-30643 with confirmed responses, including in the C797S cohort; chemotherapy combination cohorts are planned.
-   Pipeline expansion: BH-30236 Phase 1 dose escalation is ongoing in relapsed/refractory AML and high-risk MDS, with exploration of venetoclax combinations and additional myeloid indications.
-   Preclinical advancement: IND-enabling work for BH-501284 is underway with an IND planned in Q1 2027 for a pan‑KRAS candidate.
-   Operational build-out: R&D headcount has increased and the company is expanding clinical sites and manufacturing to support multiple clinical programs.
-   Liquidity runway & plans: IPO proceeds plus cash are expected to fund operations into Q2 2028, enabling a pivotal Phase 2 start for BH-30643 in 2027.

Original SEC Filing: BlossomHill Therapeutics, Inc. \[ BLSM \] - 10-Q - Sep. 18, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BLSM.US](https://longbridge.com/en/quote/BLSM.US.md)

## Related News & Research

- [BlossomHill Therapeutics to Present BH-30236 Clinical Data at ASH Meeting](https://longbridge.com/en/news/304271556.md)
- [BlossomHill Plans Pivotal Phase 2 Trial of BH-30643 in Lung Cancer for Q1 2027](https://longbridge.com/en/news/304849584.md)
- [BlossomHill Therapeutics Presents at Guggenheim’s 3rd Annual Healthcare Innovations Conference](https://longbridge.com/en/news/304110623.md)
- [KKR: ABF scaled to $91B as private IG and AI infrastructure expand the opportunity set](https://longbridge.com/en/news/304801277.md)
- [Visa (V) Just Gave Investors Something To Think About](https://longbridge.com/en/news/304838789.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**